Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peggy Manders

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Breast Cancer Research and Treatment|March 17, 2006
High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancerPaul N Span, Vivianne C G Tjan-Heijnen, Peggy Manders, et al.
Cancer|May 27, 2003
Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinomaPaul N Span, C G J Sweep, Peggy Manders, et al.
Biopreservation and Biobanking|February 14, 2018
A Stepwise Procedure to Define a Data Collection Framework for a Clinical BiobankPeggy Manders, Tessa M A Peters, Ariaan E Siezen, et al.
Oncogene|December 6, 2002
Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancerPaul N Span, Peggy Manders, Joop J Heuvel, et al.
Cancer Research|January 28, 2004
Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancerPeggy Manders, Vivianne C G Tjan-Heijnen, Paul N Span, et al.
Clinical Chemistry|June 21, 2003
Molecular beacon reverse transcription-PCR of human chorionic gonadotropin-beta-3, -5, and -8 mRNAs has prognostic value in breast cancerPaul N Span, Peggy Manders, Joop J T M Heuvel, et al.
The Journal of Pathology|April 20, 2004
Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy successPaul N Span, Raija L P Lindberg, Peggy Manders, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2004
Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival timePaul N Span, Esmé Waanders, Peggy Manders, et al.
Clinical Chemistry|September 15, 2004
Survivin is an independent prognostic marker for risk stratification of breast cancer patientsPaul N Span, Fred C G J Sweep, Erwin T G Wiegerinck, et al.
Cancer|July 27, 2004
Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinomaPeggy Manders, Vivianne C G Tjan-Heijnen, Paul N Span, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Breast Cancer Research and Treatment|March 17, 2006
High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancerPaul N Span, Vivianne C G Tjan-Heijnen, Peggy Manders, et al.
Cancer|May 27, 2003
Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinomaPaul N Span, C G J Sweep, Peggy Manders, et al.
Biopreservation and Biobanking|February 14, 2018
A Stepwise Procedure to Define a Data Collection Framework for a Clinical BiobankPeggy Manders, Tessa M A Peters, Ariaan E Siezen, et al.
Oncogene|December 6, 2002
Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancerPaul N Span, Peggy Manders, Joop J Heuvel, et al.
Cancer Research|January 28, 2004
Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancerPeggy Manders, Vivianne C G Tjan-Heijnen, Paul N Span, et al.
Clinical Chemistry|June 21, 2003
Molecular beacon reverse transcription-PCR of human chorionic gonadotropin-beta-3, -5, and -8 mRNAs has prognostic value in breast cancerPaul N Span, Peggy Manders, Joop J T M Heuvel, et al.
The Journal of Pathology|April 20, 2004
Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy successPaul N Span, Raija L P Lindberg, Peggy Manders, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2004
Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival timePaul N Span, Esmé Waanders, Peggy Manders, et al.
Clinical Chemistry|September 15, 2004
Survivin is an independent prognostic marker for risk stratification of breast cancer patientsPaul N Span, Fred C G J Sweep, Erwin T G Wiegerinck, et al.
Cancer|July 27, 2004
Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinomaPeggy Manders, Vivianne C G Tjan-Heijnen, Paul N Span, et al.
Pageof 4